Cordis Consolidation Will Help J&J Save $1.6 Billion In 2008
This article was originally published in The Gray Sheet
Executive Summary
Flagging sales of Johnson & Johnson subsidiary Cordis' Cypher drug-eluting stent will require consolidation of the business and layoffs to help ensure sustained profitable growth, J&J says